2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
2008 Clinical Practice Guidelines - Canadian Diabetes Association
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>2008</strong> CLINICAL PRACTICE GUIDELINES<br />
S32<br />
Monitoring Glycemic Control<br />
<strong>Canadian</strong> <strong>Diabetes</strong> <strong>Association</strong> <strong>Clinical</strong> <strong>Practice</strong> <strong>Guidelines</strong> Expert Committee<br />
This initial draft of this chapter was prepared by Sharon Brez RN BScN MA(Ed) CDE,<br />
Lori Berard RN CDE and Ian Blumer MD FRCPC<br />
KEY MESSAGES<br />
• Glycated hemoglobin (A1C) is a valuable indicator of<br />
treatment effectiveness, and should be measured every<br />
3 months when glycemic targets are not being met and<br />
when diabetes therapy is being adjusted.<br />
• Awareness of all measures of glycemia, including selfmonitoring<br />
of blood glucose (SMBG) results and A1C,<br />
provide the best information to assess glycemic control.<br />
• The frequency of SMBG should be determined individually,<br />
based on the type of diabetes, the treatment prescribed,<br />
the need for information about BG levels and<br />
the individual’s capacity to use the information from<br />
testing to modify behaviours or adjust medications.<br />
GLYCATED HEMOGLOBIN TESTING<br />
The <strong>Diabetes</strong> Control and Complications Trial (DCCT) (1)<br />
and the United Kingdom Prospective <strong>Diabetes</strong> Study<br />
(UKPDS) (2) demonstrated that glycated hemoglobin (A1C)<br />
and the development of long-term complications are correlated<br />
in both type 1 and type 2 diabetes, respectively. A1C is<br />
a reliable estimate of mean plasma glucose (PG) levels over<br />
the previous 3 to 4 months for most individuals (3). In<br />
uncommon circumstances where the rate of red blood cell<br />
turnover is significantly shortened or extended, or the structure<br />
of hemoglobin is altered,A1C may not accurately reflect<br />
glycemic status. A1C is a valuable indicator of treatment<br />
effectiveness and should be measured every 3 months when<br />
glycemic targets are not being met and when diabetes therapy<br />
is being adjusted. Testing at 6-month intervals may be<br />
considered in situations when glycemic targets are consistently<br />
achieved (4).<br />
Currently,A1C is the preferred standard for assessing glycated<br />
hemoglobin, and laboratories are encouraged to use<br />
assay methods for this test that are standardized to the DCCT<br />
reference (4,5). A strong mathematical relationship between<br />
mean blood glucose (BG) values and A1C levels has been<br />
identified (6). In the future, A1C may be reported as “average<br />
blood glucose” in order to assist people to better understand<br />
the meaning of the results of this test (7).<br />
SELF-MONITORING OF BLOOD GLUCOSE<br />
Awareness of all measures of glycemia, including selfmonitoring<br />
of blood glucose (SMBG) results and A1C, provide<br />
the best information to assess glycemic control (4). Most<br />
people with diabetes can benefit from SMBG (8,9). Potential<br />
benefits, which may include improvement in A1C, avoidance<br />
and identification of hypoglycemia and increased lifestyle<br />
flexibility, are enhanced when individuals receive self-management<br />
education that enables them to adjust their dietary<br />
choices, physical activity and medication(s) in response to<br />
SMBG values (8,10-14). Effective education and implementation<br />
of strategies that employ patient empowerment and<br />
behaviour change theory may be most effective in supporting<br />
the incorporation of SMBG into the diabetes management<br />
routine (10,15-18).<br />
Frequency of SMBG<br />
The frequency of SMBG should be determined individually,<br />
based on the type of diabetes, the treatment prescribed, the<br />
need for information about BG levels and the individual’s<br />
capacity to use the information from testing to modify<br />
behaviours or adjust medication.<br />
For people with type 1 diabetes, SMBG is an essential<br />
component of daily diabetes management. In a large cohort<br />
study, performance of ≥3 self-tests per day was associated<br />
with a statistically and clinically significant 1.0% reduction in<br />
A1C levels (8).The results of multiple tests each day provide<br />
information that is better correlated to A1C than fasting<br />
results alone. BG measurements taken after lunch, after supper<br />
and at bedtime have demonstrated the highest correlation<br />
to A1C (6). More frequent testing is often required to<br />
provide the information needed to reduce hypoglycemia<br />
risk, adjust treatment and make appropriate lifestyle choices.<br />
The benefits and optimal frequency of SMBG in type 2<br />
diabetes are less clear than for type 1 (8,9,12,19-26).<br />
Current evidence is at times contradictory, and methodological<br />
and conceptual limitations exist in the literature. SMBG<br />
in those who are recently diagnosed, regardless of treatment,<br />
has been demonstrated to be of benefit (24). A large cohort<br />
study found that for people with type 2 diabetes treated with<br />
oral antihyperglycemic agents, testing at least once daily was<br />
associated with a 0.6% lower A1C than less frequent monitoring<br />
(8).A more recent randomized controlled trial (RCT)<br />
of SMBG with or without instruction on how to use results<br />
for diabetes self-management failed to demonstrate improvement<br />
in glycemic control (26). However, other adequately<br />
powered RCTs, large cohort studies and consensus state-